{"schema_version":"1","generated_at":"2026-11-12T18:25:59.390Z","data_as_of":null,"url":"https://www.findmykol.com/kol/david-sommerhalder","json_url":"https://www.findmykol.com/kol/david-sommerhalder/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"david-sommerhalder","name":"David Sommerhalder","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"San Antonio","state":"TX","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"npi":"1821417270","orcid":"0000-0002-7033-9064","openalex":"A5063897579"},"summary":"David Sommerhalder is an Oncology physician. OpenAlex indexes 107 publications with 731 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":107,"cited_by_count":731,"h_index":12,"latest_activity_year":2026,"emerging":true,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT04865159","title":"Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies","phase":"PHASE1","status":"TERMINATED","role":"Overall official","sponsor":"Kura Oncology, Inc.","source_url":"https://clinicaltrials.gov/study/NCT04865159","trial_url":"https://www.findmykol.com/trial/NCT04865159"}],"source":"trials"},"payments":{"company_count":55,"program_years":{"first":2021,"last":null},"rows_total":156,"shown":3,"withheld":153,"rows":[{"payer":"Exelixis","program_year":2025,"amount_usd":638831.93,"payment_count":283,"source_url":"https://openpaymentsdata.cms.gov/search?query=1821417270"},{"payer":"AbbVie","program_year":2025,"amount_usd":387447.26,"payment_count":184,"source_url":"https://openpaymentsdata.cms.gov/search?query=1821417270"},{"payer":"Day One Biopharmaceuticals","program_year":2025,"amount_usd":343527.4,"payment_count":128,"source_url":"https://openpaymentsdata.cms.gov/search?query=1821417270"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1821417270","source":"payments"},"prescribing":{"data_year":2024,"areas_total":11,"areas_shown":3,"areas":[{"area":"Blood & clotting","share_pct":65.1,"classes_total":2,"classes":[{"class":"Parenteral Iron Replacement","setting":"administered","share_pct":64.8,"drugs":[{"name":"Iron sucrose","share_pct":100}],"max_beneficiaries":15},{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":0.3,"drugs":[{"name":"Eliquis","share_pct":62.9},{"name":"Xarelto","share_pct":37.1}],"max_beneficiaries":null}]},{"area":"Musculoskeletal","share_pct":25.9,"classes_total":1,"classes":[{"class":"RANK Ligand Inhibitor","setting":"administered","share_pct":25.9,"drugs":[{"name":"Denosumab","share_pct":100}],"max_beneficiaries":12}]},{"area":"Metabolism & gastrointestinal","share_pct":5.1,"classes_total":3,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":4.6,"drugs":[{"name":"Granisetron hydrochloride","share_pct":95.7},{"name":"Granisetron Hcl","share_pct":4.3}],"max_beneficiaries":null},{"class":"Corticosteroid","setting":"prescribed","share_pct":0.3,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":13}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer","year":2026,"journal":"New England Journal of Medicine","source_url":"https://doi.org/10.1056/nejmoa2505783","status":"verified"},{"title":"Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer","year":2026,"journal":"Nature Medicine","source_url":"https://doi.org/10.1038/s41591-026-04537-w","status":"verified"},{"title":"Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer","year":2026,"journal":"New England Journal of Medicine","source_url":"https://doi.org/10.1056/nejmoa2504059","status":"verified"},{"title":"Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-25-01525","status":"verified"},{"title":"HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results","year":2026,"journal":"Cell Reports Medicine","source_url":"https://doi.org/10.1016/j.xcrm.2026.102789","status":"verified"}],"source":"works"},"contact":{"address_1":"2829 BABCOCK RD STE 300","city":"San Antonio","state":"TX","zip":"782296011","phone":"210-580-9500","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1821417270","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":153,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2021-12-13","provider_certified":"2021-12-13","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}